-
Genetron Health brings 22 new research results in the field of cancer to the 2021 American Association for Cancer Research Annual Meeting
Time of Update: 2021-07-09
Cancer, pancreatic cancer, nervous system tumors, thymic cancer and other types of cancer, such as genetic, mutation, and fusion characteristics, verify and explore the effectiveness of multiple cancer immunotherapy markers, as well as rare cases and new therapies, thereby providing precise diagnosis and treatment methods for cancer.
-
Nuocheng Jianhua announced the latest clinical data of abutinib at the National Lymphocytic Disease Academic Conference
Time of Update: 2021-07-09
Professor Li Jianyong, leader of the Chinese Chronic Lymphocytic Leukemia (CLL) Working Group and Director of the Department of Hematology, Jiangsu Provincial People’s Hospital, shared the latest clinical application of the new BTK (Bruton's tyrosine kinase) inhibitor abutinib in the field of CLL at the conference Data .
-
World-renowned biomedicine experts assist the Pyron Biological Advisory Committee
Time of Update: 2021-07-09
Bi Honggang, senior vice president of Covance Pharmaceuticals under Labcorp, joined the advisory board of Shanghai Pyron Biotechnology Co.
Honggang Bi is currently the senior vice president of Covance Pharmaceuticals under Labcorp, the head of drug development in Asia Pacific, and the general manager of China.
-
Poinsettia subsidiary obtains the registration certificate of pantoprazole sodium for injection
Time of Update: 2021-07-09
had recently received the "Drug Registration Certificate" for pantoprazole sodium for injection approved and issued by the National Medical Products Administration .
The combination of this product with H+-K+ATPase can cause its anti-gastric acid secretion effect to last for more than 24 hours .
-
Gan Lai announced the completion of the first cohort dosing in the U.S. clinical study of THR-β agonist ASC41
Time of Update: 2021-07-09
The company announced today that the drug interactions of ASC41 oral tablet and the pharmacokinetics of non-alcoholic fatty liver disease (NAFLD) patients have completed the first cohort of drug administration in the US Phase I clinical study .
-
Kelun Pharmaceutical: Moxifloxacin Hydrochloride Eye Drops Obtained Drug Registration Approval
Time of Update: 2021-07-09
On April 15th, Kelun Pharmaceutical issued an announcement stating that the chemical drug "Moxifloxacin Hydrochloride Eye Drops" of its subsidiary Jiangxi Kelun Pharmaceutical Co.
It is reported that Moxifloxacin Hydrochloride Eye Drops was developed by Novartis.
-
Ingram Medical 700 million invested in the construction of 500,000 tons of carboxylated nitrile latex and 100,000 tons of DOTP project
Time of Update: 2021-07-09
The specific reason for the suspension of information disclosure is that timely disclosure of this cooperation matter may affect the company's relationship with the supplier at the time, and may lead to the risk of the company's nitrile latex raw material being out of supply, thereby harming the company's interests .
-
Bixime Correction Center settled in Shanghai
Time of Update: 2021-07-08
Innovative correction technology and service model are both strength and confidence At present, orthodontic patients are facing the problem of "high prices for big brands and low guarantees for small clinics".
-
Beckman Coulter and AstraZeneca jointly create a talent development ecosystem
Time of Update: 2021-07-08
" Beckman Coulter and AstraZeneca will give full play to their respective advantages in human resources, build a large health ecosystem, carry out cross-border communication and exchange of talents in a wider field and at a deeper level, and jointly benefit patients and create a win-win situation .
-
After Compaq's failure to "go to sea", Kanghong Pharmaceutical's performance "changed face" with a huge loss of 500 million
Time of Update: 2021-07-08
According to the 2017 annual report of Kanghong Pharmaceutical, the total R&D investment accounted for a significant increase in the proportion of operating income, which was mainly due to the impact of the Phase III clinical trial of the Conbercept project in the United States during the reporting period .
-
The first "China Liver Disease Management and Comprehensive Prevention and Control of Liver Cancer" Summit Forum was held
Time of Update: 2021-07-08
The first liver cancer early screening model project in Huishan District, Wuxi City, is the use of advanced screening technology in secondary prevention It is a new effective way to help more high-risk groups achieve early diagnosis and treatment and improve the five-year survival rate .
-
In 4 months, the market value has evaporated by nearly 200 billion yuan.
Time of Update: 2021-07-08
The status of "medical brother" is difficult to maintain, and the market value has evaporated by nearly 200 billion in 4 months Just before Hengrui Medicine released its 2020 and 2021 Q1 financial reports, within five trading days from April 9th to 15th, Hengrui’s stock price continued to fall from its closing price of 92.
-
Qiao Yadeng, a subsidiary of Allergan Aesthetics, was approved by the National Food and Drug Administration
Time of Update: 2021-07-08
Qiu Hanhua, General Manager of Allergan Aesthetics China, said: “The approval of Qiao Yadeng® Beauty™ fills the gap of hyaluronic acid lip injection in the Chinese medical aesthetics market.
-
Sixiang Unlimited and Jada Hexin reached a strategic cooperation and officially entered the medical aesthetics market
Time of Update: 2021-07-08
These AI technologies and live broadcast tools can help users to accurately determine their medical beauty plans and prioritize their beauty before they contact the more than 200 medical beauty institutions on the Jada Hexin medical beauty platform .
-
Operating income continues to decline, sales expenses are high, Harbin Pharmaceuticals receives annual report inquiry letter
Time of Update: 2021-07-08
The company needed to explain the problems of consecutive years of decline in the operating income of the industrial sector, the GNC bankruptcy and reorganization of investment, the significant increase in the company's management salary, and the increase in sales expenses .
-
Himalaya announces appointment of chief financial officer
Time of Update: 2021-07-08
Himalaya Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development and commercialization of new experimental antibody therapies for the treatment of solid tumor cancer based on the Conditional Active Biotechnology (CAB) technology platform in Greater China, today announced the appointment of Nicholas Desjardins ( Deng Ning) is the Chief Financial Officer and Corporate Development Officer .
-
Bluebird Bio launches Zynteglo in Europe blocked and starts layoffs
Time of Update: 2021-07-08
Due to the frustration of Zynteglo's listing on the first European market, Bluebird Bio is currently laying off employees and plans to "reduce and reshape" its workforce in parts of Germany .
-
With an investment of more than 2 billion yuan and more than 4,000 beds, why did Xinyang, a private medical institution, turn to public?
Time of Update: 2021-07-08
As far as the government or public medical institutions are concerned, in addition to the long construction period, the investment in new hospitals is also in the order of billions.
-
Saisheng Pharmaceuticals and SF Pharmaceuticals Sign Strategic Cooperation Agreement
Time of Update: 2021-07-08
Saisheng Pharmaceutical Holdings Co. , Ltd. and SF Pharmaceuticals officially announced that they will start a strategic cooperation on April 22, 2021, and SF Pharmaceuticals has become a GTP supply
-
Takeda China Ruipujia (concentrated solution for agalsidase α injection) officially launched
Time of Update: 2021-07-08
Takeda China recently announced the official launch of Ripuka® (a concentrated solution for agalsidase alpha injection) as a long-term human-derived enzyme replacement therapy for patients diagnosed with Fabry disease (α-galactosidase A deficiency) , Will provide more long-term enzyme replacement treatment options for patients with Fabre disease (α-galactosidase A deficiency) in China .
